- Eli Lilly’s three trials over the summer yielded positive results in patients with mild- to moderate-cases of coronavirus
- The company could have nearly 1 million doses ready for distribution by the end of 2020 with FDA approval
- Temporary protections provided by the antibody treatment could potentially give pharmaceutical companies more time to develop stronger vaccines
Pharmaceutical company Eli Lilly & Co. asked the U.S. Food and Drug Administration Wednesday to authorize the use of a potential coronavirus treatment that’s shown promising results during clinical trials.
Eli Lilly asked the FDA to authorize the drug’s emergency use after results for their first three clinical trials all came back positive in people with mild- to moderate-cases of coronavirus. If approved, Eli Lilly said it could have 100,000 doses ready to go within a month and 1 million ready by the end of 2020.
However, it would not be used on